154 related articles for article (PubMed ID: 31359447)
1. Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
Iurlo A; Elli EM; Palandri F; Cattaneo D; Bossi A; Cortinovis I; Bucelli C; Orofino N; Brioschi F; Auteri G; Bianchi P; Fabris S; Isimbaldi G; Sabattini E; Baldini L; Gianelli U
Hematol Oncol; 2019 Oct; 37(4):424-433. PubMed ID: 31359447
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.
Li B; Zhang P; Feng G; Xu Z; Qin T; Zhang Y; Sha Z; Dong D; Zhang H; Fang L; Pan L; Hu N; Qu S; Cai W; Huang G; Xiao Z
Blood Cancer J; 2016 Dec; 6(12):e505. PubMed ID: 27935577
[No Abstract] [Full Text] [Related]
3. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
Gianelli U; Fiori S; Cattaneo D; Bossi A; Cortinovis I; Bonometti A; Ercoli G; Bucelli C; Orofino N; Bulfamante G; Iurlo A
Histopathology; 2017 Dec; 71(6):897-908. PubMed ID: 28710830
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].
Xu ZF; Li B; Liu JQ; Li Y; Ai XF; Zhang PH; Qin TJ; Zhang Y; Wang JY; Xu JQ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):576-80. PubMed ID: 27535857
[TBL] [Abstract][Full Text] [Related]
5. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
6. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
9. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
10. Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.
Lekovic D; Gotic M; Perunicic-Jovanovic M; Vidovic A; Bogdanovic A; Jankovic G; Cokic V; Milic N
Med Oncol; 2014 Mar; 31(3):869. PubMed ID: 24500865
[TBL] [Abstract][Full Text] [Related]
11. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
Sazawal S; Singh N; Mahapatra M; Saxena R
Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
[TBL] [Abstract][Full Text] [Related]
12. The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.
Rumi E; Trotti C; Vanni D; Casetti IC; Pietra D; Sant'Antonio E
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255170
[TBL] [Abstract][Full Text] [Related]
13. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
Tefferi A; Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Am J Hematol; 2019 Mar; 94(3):299-305. PubMed ID: 30516848
[TBL] [Abstract][Full Text] [Related]
14. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
15. Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome.
Benites BD; Lima CS; Lorand-Metze I; Delamain MT; Oliveira GB; Almeida Dd; Souza CA; Vassallo J; Pagnano KB
Clinics (Sao Paulo); 2013; 68(3):339-43. PubMed ID: 23644853
[TBL] [Abstract][Full Text] [Related]
16. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
Tefferi A; Nicolosi M; Mudireddy M; Szuber N; Finke CM; Lasho TL; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Mannarelli C; Fanelli T; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Mar; 93(3):348-355. PubMed ID: 29164670
[TBL] [Abstract][Full Text] [Related]
17. Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Singh N; Sazawal S; Upadhyay A; Chhikara S; Mahapatra M; Saxena R
Indian J Pathol Microbiol; 2015; 58(2):187-91. PubMed ID: 25885131
[TBL] [Abstract][Full Text] [Related]
18. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Palandri F; Latagliata R; Polverelli N; Tieghi A; Crugnola M; Martino B; Perricone M; Breccia M; Ottaviani E; Testoni N; Merli F; Aversa F; Alimena G; Cavo M; Martinelli G; Catani L; Baccarani M; Vianelli N
Leukemia; 2015 Jun; 29(6):1344-9. PubMed ID: 25801912
[TBL] [Abstract][Full Text] [Related]
19. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
Silver RT; Barel AC; Lascu E; Ritchie EK; Roboz GJ; Christos PJ; Orazi A; Hassane DC; Tam W; Cross NCP
Cancer; 2017 Jul; 123(14):2680-2687. PubMed ID: 28518222
[TBL] [Abstract][Full Text] [Related]
20. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
